Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 87 In PIONEER 4, oral sema proved a statistically significant reduction in HbA1c and body weight at week 52 vs VictozaⓇ Mean change in HbA1c (%-point) Mean change in HbA1c - Oral sema 14 mg Mean change in body weight (kg) Oral sema 14 mg Victoza 1.8 mg Placebo 0.4 0.0 -0.4 -0.8 -1.2 -1.6 -2.0 26 Weeks Victoza 1.8 mg Placebo Mean change in body weight (kg) 0.0 • +0.2 -1.0 -2.0 • -0.9 -3.0 • -1.2* -4.0 -5.0 52 521 -6.0+ 0 26 Weeks -1.2 ⚫ -3.1 • -5.0* 52 521 1 Results illustrated by using the secondary statistical method called hypothetical estimand after 52 weeks of treatment: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide * Statistically significant versus VictozaⓇ Note: Mean baseline HbA1c: 8.0% sema: semaglutide Source: Presented at the Novo Nordisk investor event at American Diabetes Association, 78th Annual Scientific Sessions, Orlando, FL, USA novo nordisk

View entire presentation